MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy.
Recent studies in human and murine systems suggest a central role for CD4+ T cells in initiating, effecting and maintaining anti-tumor immunity. Characterization of the tumor-associated antigens recognized by CD4+ T cells may prove critical to the success of cancer immunotherapy strategies.